DO WE NEED TO DO BETTER?

Similar documents
Role of Embolic Protection during TAVR

The Case for and Against Cerebral Embolic Protection During TAVR. Susheel Kodali, MD

Building the Evidence for CEP in TAVR: A Critical Review of the Clinical Trial Data

Is Cerebral Embolic Protection Needed for TAVR?

Embolic Protection Devices for Transcatheter Aortic Valve Replacement

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center

Is Stroke Frequency Declining?

Progress in Cerebral Embolic Protection

Neuroprotection During TAVR

Why Cerebral Protection after TAVR Will Become the Standard of Care

Alexandra Lansky, MD Yale University School of Medicine University College London

Sentinel Dual Filter Device: Technology Overview and Status of the CLEAN-TAVI Randomized Trial. Martin B. Leon, MD

Accepted Manuscript. Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Disconnect Between Logic and Data?

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

Post-TAVI Cerebral Embolisms and Potential Protection Means

Transcatheter Aortic Valve Replacement

The Role of TAVI in high-risk and normal-risk Patients

Complicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato

Cerebral Embolic Protection In Patients Undergoing Surgical Aortic Valve Replacement (SAVR)

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

The Sentinel Dual Filter Device Design Features & EU Clinical Trial Results

e Corrado Tamburino, MD, PhD

Protection Devices for Stroke Prevention Do the Data support their Routine Use?

Strokes After TAVR Reasons for Declining Frequency

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Update on TAVR. Howard C. Herrmann, MD, FACC, MSCAI

Cerebral Protection In Transcatheter Aortic Valve Replacement The SENTINEL Study. Susheel Kodali, MD Columbia University Medical Center

Transcatheter heart valve thrombosis

Subclinical Thrombosis of Bioprosthetic Aortic Valves: Is It Clinically Relevant? Tarun Chakravarty, MD

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

Trans Aortic Valve Replacement Update: 2016 & Beyond

How to Prevent Thromboembolic Complications in TAVI

Antithrombotic. DAPT or OAC?

The Silent and Apparent Neurological Injury in Transcatheter Aortic Valve Implantation Study (SANITY)

Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?

Role of Embolic Protection Devices in TAVR: Are They Needed? Waste of Time and Money?

Le TAVI pour tout le monde?

STROKE PREVENTION IN AORTIC ARCH PROCEDURES

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Current Controversies. Subclinical and clinical valve thrombosis

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington

Strokes After TAVR. Incidence (past and present) Multi-factorial Origin

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

Mild paravalvular regurgitation is not an independent predictor of mortality following TAVI

Strokes After TAVR: Perspectives from the US CoreValve Trials

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

Cerebral protection devices in transcatheter aortic valve replacement: a clinical meta-analysis of randomized controlled trials

TAVR and Cardiac Surgeons

The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent

Risk and Fate of Cerebral Embolism After Transfemoral Aortic Valve Implantation

Disclosures. LGH TAVR: Presentation Outline 2/2/2016. Updates in Transcatheter Aortic Valve Replacement (TAVR) and the LGH Experience

Davos Cerebral Ischemia after Transcatheter Aortic Valve Implantation. Raimund Erbel, H Eggebrecht, P Kahlert for the

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

TAVR: Review of the Robust Data from Randomized Trials

The risk of air embolism in TEVAR and how to handle it!

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Strokes After TAVR Multi-factorial Origin, Incidence (past and present), and Management Considerations (present and future)

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

Paravalvular Regurgitation is a Risk Factor Following TAVI

Disclosure. Advances in Interventional Neurology. Disclosure. Natural History of Disease 3/15/2018. Vishal B. Jani MD

Therapy for Acute Stroke. Systems of Care for TIA

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Pre- Cardiac intervention. Dr. Victor Sim 16 th Oct 2014

TAVI limitations for low risk patients

Prof. Fiorenzo Gaita

Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study

TAVR for low-risk patients in 2017: not so fast.

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Low Gradient Severe? AS

Left Atrial Appendage Occlusion

For the SURTAVI Investigators

Peri-Surgical Anemia and the TAVR Patient

Valvular Intervention

Complications after TAVI: VARC Definitions, Frequency and Management Considerations Patrick W. Serruys, Nicolo Piazza,

Limitations of Other Embolic Protection Devices - Filters. Carotid Stenting with Flow Reversal. Limitations of Distal Occlusion

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

L evoluzione nel management della valvulopatia aortica

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea

How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention

TAVI EN INSUFICIENCIA AORTICA

TAVR: Intermediate Risk Patients

Outcomes in the Commercial Use of Self-expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and

Emergently? Michigan Institute for Neurological Disorders. Garden City Hospital, Garden City, Michigan

The Heart Team and the minimalist approach to TAVR today Is there a conflict? G T Stavridis MD FETCS Onassis Cardiac Surgery Ctr.

Aortic Valve Stenosis: Flow and Gradient stratification and association with TAVR outcomes

Indication, Timing, Assessment and Update on TAVI

Pre- Cardiac intervention. Dr. Victor Sim 26 th Sept 2014

Trans Catheter Aortic Valve Replacement

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization.

Will Mesh-covered Stents Help Reduce the Risk of Stroke? Peter A. Schneider, MD Kaiser Foundation Hospital Honolulu, Hawaii

BGS Spring Risk Factors and Preventative Strategies for Dementia

TAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology

2016 Update in Geriatrics Elizabeth Eckstrom, MD, MPH Oregon Health & Science University Oregon Geriatrics Society October 7, 2016

ANTICOAGULATION IN SPECIFIC POPULATIONS: BIOLOGICAL HEART VALVES, TAVI

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

Transcription:

A critical review of the neurological effects of invasive cardiac procedures: DO WE NEED TO DO BETTER? Pieter Stella, MD, PhD University Medical Center Utrecht, The Netherlands

Disclosure - Member Advisory Board Keystone Heart - Consultant DEKRA CE - Physician Proctor Edwards Lifesciences

Incidence of Symptomatic Stroke after Invasive procedures *Stolz 2004, Knipp 2005 ** Ghanem 2010, Kahlert 2010

Incidence of New DW MRI Brain Lesions *Stolz 2004, Knipp 2005 ** Ghanem 2010, Kahlert 2010

Estimated Annual US Incidence of New Brain Lesions 2013 *Gress- JACC 2012

ACUTE NEUROLOGICAL RISK AFTER BRAIN EMBOLI Overt CNS injury; Ischemic stroke, clinical symptoms >24 hours or <24 hours with imaging confirmation TIA and delirium without imaging confirmation Covert CNS injury; imaging findings without clinical symptoms Lansky A, Messe S, Baumbach A et al. NeuroARC; JACC 2017 and EHJ 2017, h t t p : / / d x. d o i. o r g / 1 0. 1 0 1 6 / j. j a c c. 20 1 6. 1 1. 0 4 5

The Incidence of Overt stroke after TAVR; 9-14% Clinical Symptoms with Imaging findings, neurologists seen each patient % 30 25 20 15 10 5 0 Overt stroke Mistral Messe (SAVR) DIII NeuroTAVR CLEAN TAVI SENTINEL

The Incidence of Covert CNS Injury after TAVR Considering that about 15% of patients have also clinical symptoms assessed by neurologist, the incidence of covert CNS injury post TAVR is about 60% of all patients.

One Out of Three Patients without Cerebral Embolic Protection have Worsening Cognition with new MRI Lesions After TAVR The NeuroTAVR data (conducted only in the USA on neurological changes after TAVR without cerebral embolic protection) also demonstrated that 33.3% of patient had worse MoCA scores at discharge as compared to baseline 40.6% of patient had worse MoCA scores at 30-Days post procedure as compared to baseline Lansky AJ et al. European Heart Journal 2015, 36, (31); 2070 2078 https://doi.org/10.1093/eurheartj/ehv191 Lansky, Alexandra J. et al. American Journal of Cardiology, Volume 118, Issue 10, 1519 1526

Both TIA and Delirium Increase the Risk of Long-Term Mortality after TAVR Survival after TIA (Partner trial) The incidence of post operative delirium after TAVI is high, 14.5% A higher number of DW MRI lesions after TAVI is associated with a higher incidence of postoperative delirium following TAVI* Post-op delirium in TAVR patients has been shown to lead to a 3-fold increase in both post-procedural and long-term mortality** Post-op delirium can lead to extended length of stay and in-hospital complications as well as an increase in health care costs of between $16,000 to $64,000 per patient*** Kapadia et al https://doi.org/10.1161/circinterventions.115.002981 Circulation: Cardiovascular Interventions. 2016;9:e002981 * Stella P, TCT 2016 **Giuseffi JL, J Am Coll Cardiol. 2014;63:12, Abawi M, J Am Coll Cardiol Intv. 2016;9:160 *** Leslie DL, J Am Geriatr Soc. 2011;59:S241

Lesion Volume Correlates with Cognitive Impairment and is Related to Mental Change Relationship between Volume of Cerebral DWI Lesions and Cognitive Function Patients with acute mental changes have significantly more lesions and larger mean lesion volume compared to patients without acute post-procedural mental changes Bonati et al. Lancet 2010; 375: 985 997 Choi SH et al. Neurology. 2000;54(1):83-89

Long term Consequences of Decreased Brain Reserve Loss of Brain Tissue On average 294.7 mm3 loss of brain tissue, each NeuroTAVR patient lost potentially during the unprotected TAVI procedure: 23.6 Million Neurons and 1.33 Billion synapses (10 MAY 2013 VOL 340 SCIENCE). Reduced brain reserve increases the risk of: dementia depression Parkinson s disease Alzheimer s disease, and overall neuro-cognitive decline In addition, after TAVR clinically silent brain infarcts are associated with over 2 fold increase of dementia and over 3 fold increase of a clinically evident stroke Lansky, Alexandra J. et al. American Journal of Cardiology, Volume 118, Issue 10, 1519 1526 Restrepo, L. et al Stroke 2002; 33:2909 2915, Lund C., et al. EHJ 2005, Vol 26 (13):1269-1275,, Messe SR et al. Circulation 2014;129:2253-61., Miller DC, et al. J Thorac Cardiovasc Surg. 2012;143:832-843 e813, Schwarz et al. Am Heart J. 2011 Oct;162(4):756-63. Knipp SC et al. Ann Thorac Surg 2008;85:872-9., Vermeer, S. et al. N Engl J Med 2003; 348:1215-1222 March 27, 2003 DOI:, 10.1056/NEJMoa022066, Vermeer, S., et al. Stroke 2003; 34:1126 1129

Summary Multiple CV treatments have a risk of brain emboli. Brain lesions impact Brain function! TAVR now under investigation, but not the only cause! Need to focus to minimize all adverse events, especially cerebral damage, while further advancing patient care.